

Special Issue

Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy

Message from the Guest Editors

The goal of cancer immunotherapy is to induce regression of solid and hematological malignancies, indirectly attacking the cancer by regulating the patient's immunity, establishing perduring antitumour memory and limiting adverse reactions. Combining conventional methods for cancer treatment such as surgery, chemotherapy and radiation therapy with improved immunotherapy approaches might overcome tumour resistance and enhance clinical efficacy. Similarly, the success of vaccine-based immunotherapy might be reinforced by other cutting-edge approaches such as immune checkpoint inhibitor, adoptive cell transfer and engineered T-cell therapy. In this Special Issue, we want to deliberate on how to improve therapeutic cancer immunotherapies by discussing the potential problems and solutions for overcoming tumour resistance and enhancing clinical efficacy. Similarly, we would like to take advantage of novel knowledge and technologies, in order to reach the next breakthrough in cancer immunotherapy. We warmly welcome all scientists working in these fields to submit their manuscripts to our Special Issue.

Guest Editors

Dr. Lionel Poulin

U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille,
Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France

Prof. Dr. Damya Laoui

1. Laboratory for Cellular and Molecular Immunology, Vrije Universiteit Brussel, 1040 Brussels, Belgium
2. Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, 1040 Brussels, Belgium

Deadline for manuscript submissions

closed (31 October 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/103723

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).